Radiation Retinopathy and Neuropathy following Plaque Therapy of Small Choroidal Melanoma

Author(s):  
D. Wilkinson ◽  
V. Torres ◽  
M. Kolar ◽  
P. Fleming ◽  
A. Singh
2018 ◽  
Vol 9 (1) ◽  
pp. 23-29
Author(s):  
Daisaku Kimura ◽  
Teruyo Kida ◽  
Takaki Sato ◽  
Masanori Fukumoto ◽  
Ryohsuke Kohmoto ◽  
...  

Purpose: To report a case of retinal detachment with unique optical coherence tomography (OCT) findings after Gamma Knife® (GK; Elekta Instrument AB, Stockholm, Sweden) treatment for choroidal melanoma (CM). Case Report: A 48-year-old woman underwent GK therapy for CM in her right eye from the macula to the temporal side. While the tumor subsequently shrank, the patient developed radiation retinopathy, which was treated with laser photocoagulation. The tumor lesions later subsided; however, her visual acuity (VA) decreased 8 years after the initial treatment. Although the tumor lesions in the right eye had become scarred, a bullous retinal detachment with fixed folds occurred in the superior-nasal quadrants. OCT examination revealed a preretinal membrane, vitreoretinal traction, and an inner retinal break; however, no outer retinal break was clearly detectable. MRI scans showed no increase in tumorous lesions, and 123I-IMP SPECT imaging showed no photon accumulation. Thus, it was determined that there was no tumor activity. The corrected VA in her right eye was light perception, and it was determined that there was no indication for vitreous surgery. Conclusion: In this case, an inner retinal break was formed by the vitreoretinal traction around the scarred tumor and radiation retinopathy, thus suggesting the possibility of the development of a rhegmatogenous retinal detachment presumably complicated with an outer retinal break.


Ophthalmology ◽  
2002 ◽  
Vol 109 (5) ◽  
pp. 909-913 ◽  
Author(s):  
Anton Haas ◽  
Oliver Pinter ◽  
Georg Papaefthymiou ◽  
Martin Weger ◽  
Andrea Berghold ◽  
...  

2018 ◽  
Vol 256 (9) ◽  
pp. 1599-1604
Author(s):  
Catharina Busch ◽  
Julia Löwen ◽  
Daniel Pilger ◽  
Ira Seibel ◽  
Jens Heufelder ◽  
...  

2020 ◽  
Vol 258 (4) ◽  
pp. 869-878 ◽  
Author(s):  
Ira Seibel ◽  
Daniela Vollhardt ◽  
Aline I. Riechardt ◽  
Matus Rehak ◽  
Sabine Schmied ◽  
...  

Abstract Purpose To demonstrate superiority of intravitreal ranibizumab 0.5 mg compared to focal and peripheral laser treatment in patients with radiation retinopathy for choroidal melanoma. Methods Inclusion criteria were as follows: patients with radiation retinopathy and visual acuity impairment due to radiation maculopathy accessible for laser therapy, age ≥ 18 years, and BCVA less than 20/32. The main objective was to study the change in best-corrected visual acuity (BCVA) over 6 months from ranibizumab 0.5 mg (experimental) compared to focal laser of the macula and panretinal laser treatment of the ischemic retina (control) in patients with radiation retinopathy in choroidal melanoma. The secondary objectives of the radiation retinopathy study were to compare functional and anatomical results between ranibizumab and laser group over 12 months and to measure the frequency of vitreous hemorrhage and rubeosis iridis. Results The intention-to-treat analysis included 31 patients assigned to ranibizumab (n = 15) or laser treatment (n = 16). In terms of BCVA at month 6, ranibizumab was superior to laser treatment, with an advantage of 0.14 logMAR, 95% CI 0.01 to 0.25, p = 0.030. The positive effect of ranibizumab disappeared after treatment was discontinued. Similar results without statistically significant difference were found with respect to macular thickness. In both groups, no change was observed at month 6 in the size of ischemia in the macula or periphery compared to baseline. There was 1 case of vitreous hemorrhage in the laser group and no case of rubeosis iridis over time. Conclusions This study showed a statistically significant improvement in visual acuity and clear superiority of ranibizumab compared to laser treatment up to 26 weeks, but this effect disappeared at week 52 after completion of intravitreal treatment. Ranibizumab and PRP are considered equivalent in terms of the non-appearance of proliferative radiation retinopathy during the study. Trial registration EudraCT Number: 2011-004463-69


Sign in / Sign up

Export Citation Format

Share Document